Immediate Impact

1 from Science/Nature 61 standout
Sub-graph 1 of 23

Citing Papers

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
2022 Standout
2 intermediate papers

Works of J Rosai being referenced

Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
2005

Author Peers

Author Last Decade Papers Cites
J Rosai 373 82 63 245 176 10 559
Xiao‐ge Zhou 479 64 13 91 107 13 603
Alejandra Zárate‐Osorno 254 51 119 42 138 21 528
Neïla Benameur 98 23 122 480 177 12 627
Dariusz Stachurski 347 25 36 122 27 14 550
Chin-Yang Li 138 66 31 54 93 14 569
ST Yuen 123 162 89 75 49 13 507
William D. Wehunt 185 141 97 70 85 11 553
Juan Herrada 326 19 77 147 184 13 642
L Marelle 433 92 15 40 41 9 531
Anne Y. Matsushima 234 86 59 28 45 13 635

All Works

Loading papers...

Rankless by CCL
2026